Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 43K 39.75K 36.72K 69.15K 4.73M 70.41K 474K 186K 2.31M 185K 181K 7.97M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.62M 4.27M 3.95M 7.44M 508M 7.57M 50.97M 20M 249M 19.87M 19.43M 857M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
11/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	-3.58%	-10.71%	+9.58%	-27.50%	3.15B
SAREPTA THERAPEUTICS, INC.	-4.57%	-9.25%	-6.60%	-83.34%	1.9B
BIONOTE, INC.	0.00%	-1.93%	-13.42%	-16.58%	311M
DK LIFE SCIENCE CO., LTD.	-2.11%	-6.45%	-48.62%	-	49.86M
Average	-2.05%	-2.93%	-14.77%	-42.47%	1.08B
Weighted average by Cap.	-3.71%	-4.14%	+2.04%	-46.65%

	2014	2015
Net sales	26.11M 22.82M 21.09M 19.49M 36.7M 2.51B 37.37M 252M 98.7M 1.23B 98.08M 95.91M 4.23B	17.88M 15.63M 14.45M 13.35M 25.14M 1.72B 25.59M 172M 67.6M 841M 67.18M 65.69M 2.9B
Net income	-8.47M -7.4M -6.84M -6.32M -11.9M -813M -12.12M -81.57M -32M -398M -31.8M -31.1M -1.37B	-7.17M -6.26M -5.79M -5.35M -10.07M -688M -10.25M -69.04M -27.09M -337M -26.92M -26.32M -1.16B
Net Debt	-198K -173K -160K -148K -278K -19.02M -283K -1.91M -748K -9.31M -744K -727K -32.07M	5.24M 4.58M 4.23M 3.91M 7.37M 503M 7.5M 50.49M 19.81M 247M 19.69M 19.25M 849M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile